The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Sir,
The lines of Blaschko are postulated to correspond to the migration of ectodermal and neuroectodermal cells during embryogenesis. [1] Genetic mosaicism is pathomechanism behind segmental/blaschkoid distribution of lesions. It refers to the habitation of two or more genetically distinct cell populations derived from same zygote. Colocalization phenomenon is not uncommon in dermatologic disorders. But concomitance of two different pigmentary disorders in a blaschkoid distribution is a rare phenomenon, under reported.
A 7-year-old female student presented with 6 months history of depigmented patches and 4 months history of hyperpigmented patches over the left side of her face. The lesions had insidious onset, progressive, and asymptomatic. There was no history of preceding raised/erythematous lesions and no similar history in the family. Clinical examination revealed well-defined confluent and discrete depigmented patches over the left periorbital area extending to left zygomatic area, left temporal area, left pinna, and left side of occipital scalp, also there was presence of discrete and confluent hyperpigmented brownish patches over chin extending to the left side of neck in a linear pattern and few similar patches over left cheek [ Figure 1a and b]. Dermoscopy and histopathological examination was done and was consistent with lichen planus pigmentosus (LPP) [ Figure 2a and b]. With a diagnosis of segmental vitiligo and LPP, patient was treated with topical tacrolimus 0.1% ointment followed by partial repigmentation of depigmented patches and no change in hyperpigmented patches at the end of 2 months. Segmental vitiligo is characterized by depigmented patches over skin in a dermatomal distribution. Pathomechanisms suggested are somatic mosaicism
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Letters to the Editor or neurogenic cause. [1] Blaschkoid LPP is sparingly reported in the literature and mosaicism is suggested in this disorder too. [2] LPP has rarely been reported as associated with vitiligo in the literature. It has been seen that lichen planus may develop over lesions of vitiligo, or may occur both on vitiligo and on normal skin, or it may develop at a different site than on vitiligo lesions. Both the diseases are autoimmune in nature; and two autoimmune skin diseases can occur together. Another reason for co-occurrence of lesions has been suggested to be because of actinic damage in non-pigmented skin, leading to abnormal immune response. [3] Another theory suggested that vitiligo alters the antigens identified by effector T cells in lichen planus. [4] It has also been suggested that the Koebner's phenomenon may be implicated in the causation. The association of co-occurrence of segmental vitiligo and blaschkoid LPP has been shown as a single case in the literature suggesting the role of mosaicism. [2] There are very few reports of blaschkoid LPP presenting on the face, trunk, and limbs. The Blaschko's lines are thought to reflect T-lymphocytic migration and the clonal expression during the embryogenesis of the skin. [5] The genetic mosaicism is an acquired Blaschko-linear inflammatory dermatosis, could be responsible for this cutaneous antigenic mosaicism that may induce a mosaic T-cell response against an environmental trigger. [5] In our case, two pigmentary disorders in blaschkoid pattern in same segment of body represent a rare association and an effect of acquired pigmentary mosaicism. 
Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis
Sir, Secukinumab is a recombinant, fully human IgG1 monoclonal antibody which selectively binds and neutralizes interleukin 17A (IL-17A). IL-17 is secreted by a class of helper T cells called Th17 cells, which stimulates keratinocytes to secrete proinflammatory mediator and to recruit other inflammatory cells in psoriatic skins. Secukinumab was FDA approved in January 2015 for the management of plaque psoriasis, and in January 2016 for the management of psoriatic arthritis. It is the one of the biologic approved as first-line therapy for the management of chronic plaque psoriasis. Pooled safety data from 10 Phase II/III studies have showed that secukinumab is a reasonably safe drug and serious adverse effects are uncommon. Infections like nasopharyngitis and upper respiratory tract infection were most common. Serious infections were infrequent, and reactivation of latent tuberculosis was not seen. Mucocutaneous candidiasis was more common in patients treated with secukinumab. Other adverse effects due to secukinumab are neutropenia, nonmelanoma skin cancer (NMSC), major adverse cardiac events (MACE), and inflammatory bowel disease. Neutropenia is rare and mostly Grade 1 or 2. The risk of NMSC and MACE is comparable to patients on TNF inhibitors and IL-12/23 blocker and is quite rare. [1] [2] [3] We hereby present a case of chronic plaque psoriasis whom we treated with secukinumab and the patient developed widespread tinea corporis 4 weeks after starting the therapy.
A 38-year-old male patient, with no known comorbidities but known case of chronic plaque psoriasis for 4 years, presented with acute exacerbation of his illness for the last 1 month. His previous treatments included topical steroids, narrow-band ultraviolet B therapy, and methotrexate. He was not on any treatment for the last 6 months. General and systemic examinations were within normal limits. Dermatological examination
